Why Agios Pharmaceuticals Inc (AGIO) Stock Is Rising
As of 2026-11-12, Agios Pharmaceuticals Inc (AGIO) has a next-year EPS growth estimate of 41.98%. Featured in 2 EPS revision reports, most recently on 2026-10-21.
Why AGIO Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Agios Pharmaceuticals Inc's next-year EPS growth estimate from 37.02% to 42.12% on 2026-11-06.
- !Largest Single-Day Revision: +2.60 pp on 2026-11-10 (39.38% → 41.98%).
- ·Current-Year Growth: Projected at 21.94%, supporting the forward estimate revision.
News Context
The primary structural driver is the Nov. 6, 2026 upgrade to AGIO’s next-year EPS growth estimate from 37.02% to 42.12%, now at 39.38%. This is plausibly connected to Q3 results showing an earnings beat and record mitapivat sales, plus FDA priority review of the sickle-cell sNDA
Generated 2026-11-10 · news as of 2026-11-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 41.98%
- EPS growth this year
- 21.94%
- EPS next quarter (est)
- -$1.09
- Last price
- $31.76
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 41.98% | 21.94% | -$1.09 | $31.76 |
| 2026-11-11 | 41.98% | 21.94% | -$1.09 | $32.82 |
| 2026-11-10 | 41.98% | 21.94% | -$1.09 | $31.76 |
| 2026-11-09 | 39.38% | 22.33% | -$1.06 | $31.38 |
| 2026-11-07 | 42.12% | 21.64% | -$1.07 | $29.41 |
| 2026-11-06 | 42.12% | 21.64% | -$1.07 | $29.41 |
| 2026-11-05 | 37.02% | 18.86% | -$1.15 | $28.27 |
| 2026-11-04 | 35.07% | 18.92% | -$1.24 | $31.38 |
| 2026-11-03 | 35.07% | 18.92% | -$1.24 | $31.20 |
| 2026-11-02 | 35.07% | 18.92% | -$1.24 | $29.95 |
| 2026-10-31 | 35.07% | 18.92% | -$1.24 | $30.55 |
| 2026-10-30 | 35.07% | 18.92% | -$1.24 | $30.55 |
| 2026-10-29 | 35.07% | 18.92% | -$1.24 | $37.23 |
| 2026-10-28 | 34.68% | 19.04% | -$1.25 | $38.12 |
| 2026-10-27 | 34.68% | 19.04% | -$1.25 | $38.03 |
| 2026-10-26 | 34.68% | 19.04% | -$1.25 | $36.85 |
| 2026-10-23 | 34.68% | 19.04% | -$1.25 | $37.00 |
| 2026-10-22 | 34.68% | 19.04% | -$1.25 | $37.19 |
| 2026-10-21 | 34.93% | 19.31% | -$1.24 | $37.18 |
| 2026-10-20 | 34.93% | 19.31% | -$1.24 | $36.64 |
| 2026-10-19 | 34.93% | 19.31% | -$1.24 | $34.90 |
| 2026-10-16 | 34.93% | 19.31% | -$1.24 | $31.32 |
| 2026-10-15 | 34.93% | 19.31% | -$1.24 | $32.32 |
| 2026-10-14 | 34.91% | 19.29% | -$1.24 | $30.97 |
| 2026-10-13 | 34.91% | 19.29% | -$1.24 | $30.21 |
| 2026-10-12 | 34.91% | 19.29% | -$1.24 | $30.82 |
| 2026-10-11 | 34.91% | 19.29% | -$1.24 | $31.81 |
| 2026-10-10 | 34.91% | 19.29% | -$1.24 | $31.81 |
| 2026-10-09 | 34.91% | 19.29% | -$1.24 | $31.81 |
| 2026-10-08 | 34.95% | 19.31% | -$1.24 | $31.92 |
Reports Featuring AGIO
Recent News
- Agios Beats On Record Mitapivat Sales, But A Sickle Cell Delay And Slowing Script Adds Complicate The StoryEarnings Whispers
- Agios Pharmaceuticals: Q3 Earnings SnapshotAssociated Press
- Agios Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- AGIO Stock Hits Over 7-Month Highs FDA Catalyst, Seasonally Strong Q2 Earnings Estimate Drive OptimismStocktwits
- U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell DiseaseGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Agios Pharmaceuticals Inc (AGIO) stock go up recently?▾
Agios Pharmaceuticals Inc (AGIO) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 37.02% to 42.12% on 2026-11-06. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Agios Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Agios Pharmaceuticals Inc (AGIO) has a next-year EPS growth estimate of 41.98%, based on analyst consensus.
When was the latest EPS estimate revision for AGIO?▾
The most recent revision occurred on 2026-11-10, when analysts adjusted the next-year EPS growth estimate from 39.38% to 41.98%.
What sector and industry does Agios Pharmaceuticals Inc belong to?▾
Agios Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AGIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Agios Pharmaceuticals Inc (AGIO) appears here because it was detected by our daily top-EPS-revision-performer screen.